<?xml version="1.0" encoding="UTF-8"?>
<p>In light of the toxicological profile of LPV/r and its high potential for drugâ€“drug interactions, China National Center for Adverse Drug Reaction Monitoring collected and analyzed data from hospitals concerning medication safety for COVID-19 patients; their report included the following findings: 179 patients (82.5%) developed adverse effects after the lopinavir/ritonavir treatment and 37 patients (17.1%) after chloroquine use. The adverse effects related to LPV/r use consisted of the following: hypertriglyceridemia, hypercholesterolemia, gastrointestinal reactions (diarrhea), liver injury, and rush [
 <xref rid="B115-jcm-09-02084" ref-type="bibr">115</xref>].
</p>
